Alvine names new senior vice president and chief medical officer

Prior to joining Alvine Pharmaceuticals, Dr Adelman was senior vice president of development and chief medical officer at Sunesis Pharmaceuticals. Prior to that, Dr Adelman served in various roles at Pharmacyclics including vice president of clinical operations and biometrics and was a clinical scientist at Genentech.

Dr Adelman holds a BA in biology from the University of California, Berkeley and an MD degree from the University of California, Davis.

Abhay Joshi, president and CEO of Alvine, said: “I am extremely pleased to welcome Dan to Alvine’s management team. His drug development expertise in biopharmaceuticals will be of great value to Alvine as the company advances its lead compound, ALV003 into Phase II clinical trials this year. I am confident that Dan will be a key contributor to our development of a successful therapy for the treatment of celiac disease.”